The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.

about

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.

Item

http://www.wikidata.org/entity/Q48523391

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

The PANDA study: a randomized ...... ic colorectal cancer patients.

@en

The PANDA study: a randomized ...... ic colorectal cancer patients.

@nl

type

Item

label

The PANDA study: a randomized ...... ic colorectal cancer patients.

@en

The PANDA study: a randomized ...... ic colorectal cancer patients.

@nl

prefLabel

The PANDA study: a randomized ...... ic colorectal cancer patients.

@en

The PANDA study: a randomized ...... ic colorectal cancer patients.

@nl

P1476

The PANDA study: a randomized ...... tic colorectal cancer patients

@en

P2093

Alessandro Passardi

http://www.w3.org/2001/XMLSchema#string

Ermenegildo Arnoldi

http://www.w3.org/2001/XMLSchema#string

Eufemia Stefania Lutrino

http://www.w3.org/2001/XMLSchema#string

Federica Buggin

http://www.w3.org/2001/XMLSchema#string

Giorgia Boscolo

http://www.w3.org/2001/XMLSchema#string

Giuseppe Tonini

http://www.w3.org/2001/XMLSchema#string

Jessica Lucchetti

http://www.w3.org/2001/XMLSchema#string

Luca Boni

http://www.w3.org/2001/XMLSchema#string

Mario Scartozzi

http://www.w3.org/2001/XMLSchema#string

Nicoletta Pella

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.

First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.

Colorectal cancer statistics, 2017.

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.

Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.

Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013.

P2888

s12885-018-4001-x

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-018-4001-X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1100622516

http://www.w3.org/2001/XMLSchema#string

P698

29370781

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5784655

http://www.w3.org/2001/XMLSchema#string